ImmunityBio, Inc. (IBRX)
|52 Week Range||1.21-7.1|
|1y Target Est||-|
|DCF Unlevered||IBRX DCF ->|
|DCF Levered||IBRX LDCF ->|
|Debt / Equity||-174.21%||Sell|
Upgrades & Downgrades
Latest IBRX news
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
27 November 2023
ImmunityBio, Inc. (IBRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IBRX's 50-day simple moving average broke out above its 200...
3 Biotech Moonshots to Bet on the Future of Health
6 November 2023
Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular, ...
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
3 November 2023
Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better unders...
ImmunityBio: The CRL Makes It Riskier Than Ever
24 October 2023
ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspectio...
Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP
15 September 2023
Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily sho...
Why Shares of ImmunityBio Jumped This Week
15 September 2023
The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million.
3 Very Oversold Biotech Stocks to Buy Right Now
29 August 2023
After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very relu...
Looking for a Bargain? 3 Biotech Stocks to Buy That Are Down 20%-60% in 2023
1 August 2023
American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable ...
Why Shares of ImmunityBio Were Up on Wednesday
19 July 2023
ImmunityBio is a clinical-stage biotech company. The company's lead therapy candidate is Anktiva.